In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study
Journal of Thrombosis and Haemostasis · 2023
DOI: 10.1016/j.jtha.2023.08.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Maxime Fieux und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, F-69310, Pierre Bénite, Fra…. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk, Hospices Civils de Lyon, Université Claude Bernard Lyon 1.
Abstract (Originalsprache)
BACKGROUND: Hemophilia B (HB) is a bleeding disorder characterized by coagulation factor (F) IX (FIX) deficiency. The current standard-of-care for severe HB is prophylaxis with long-term repetitive intravenous (i.v.) infusions of recombinant FIX (rFIX) with standard half-life or extended half-life. Unmet needs remain regarding the development of non-invasive administration routes for coagulation factors. The aim of this study was to evaluate the effectiveness of intranasal delivery (IND) of rFIX and rFIX fused to Fc fragment (rFIX-Fc) in mice. METHODS: Drops of rFIX and rFIX-Fc were deposited in the nostrils of wild-type, FcRn knock-out, FcRn humanized, and FIX knock-out mice. rFIX mucosal uptake was evaluated by measuring plasma FIX antigen and FIX activity (FIX:C) levels, and by performing histologic analysis of the nasal mucosa following IND. RESULTS: After IND, both rFIX and rFIX-Fc were equally delivered to the blood compartment, irrespective of the mouse strain studied, mostly through a passive mechanism of transportation across the mucosal barrier, independent of FcRn receptor. Both plasma FIX antigen and FIX:C activity levels increased following IND in FIX knock-out mice. CONCLUSION: This proof-of-concept study describes evidence supporting the nasal route as an alternative to FIX i.v. infusion for the treatment of HB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, F-69310, Pierre Bénite, France; Université de Lyon, Université Lyon 1, F-69003, Lyon, France; Uni…
- UMR 5305, Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, Institut de Biologie et Chimie des Protéines, CNRS/Université Claude Bernard Lyon 1, 7 Passage du Vercors, CEDEX 07, 69367 Lyon, France.
- EA 4609 Hémostase et cancer, Université de Lyon, Université Lyon 1, F-69003, Lyon, France.
- Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France; CNRS EMR 7000, F-94010 Créteil, France; Centre Hospitalier Intercommunal de Créteil, Service d'Oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale, F-940…
- EA 4609 Hémostase et cancer, Université de Lyon, Université Lyon 1, F-69003, Lyon, France; Unité d'hémostase clinique, Centre National de Référence de l'hémophilie, Hospices Civils de Lyon, France. Electronic address: s…
Förderung
- Novo Nordisk
- Hospices Civils de Lyon
- Université Claude Bernard Lyon 1
- Fonds de dotation CSL Behring pour la recherche
Zitieren
APA
Fieux, M., Rovera, R., Coiffier, C., Colomb, E., Enjolras, N., Béquignon, E., Monge, C., & Le Quellec, S. (2023). In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.08.019
Vancouver
Fieux M, Rovera R, Coiffier C, Colomb E, Enjolras N, Béquignon E, et al. In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.08.019
BibTeX
@article{Fieux2023,
author = {Fieux, Maxime and Rovera, Renaud and Coiffier, Céline and Colomb, Evelyne and Enjolras, Nathalie and Béquignon, Emilie and Monge, Claire and Le Quellec, Sandra},
title = {In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
doi = {10.1016/j.jtha.2023.08.019}
}
EUVIMED